Dioxel is a medication prescribed to assist in the management of symptoms associated with certain inflammatory and autoimmune conditions in adults. The primary therapeutic focus is on rheumatoid arthritis and psoriatic arthritis, conditions where the medicine is used to support the reduction of inflammation. It is also considered for therapeutic planning in specific cases of inflammatory bowel disease to help manage related symptoms and discomfort.

The central benefit provided by Dioxel is the potential to aid in improving functional movement and support the long-term control of the condition's activity, helping patients maintain a better quality of life. The medication is an available option when standard initial treatments have not achieved the necessary level of symptom support.

---

Quick Fact: Relief for Joint Discomfort

Dioxel is designed to help address joint stiffness and associated discomfort in adults with chronic inflammatory conditions, supporting efforts toward daily physical function.

The eligibility profile for Dioxel is strictly defined by regulatory guidelines, establishing clear rules for use and exclusion based on population and clinical status. The medicine is permitted for use only in adults under standard labeled conditions.

Contraindications and Absolute Non-Eligibility

Use is strictly contraindicated for patients with a known hypersensitivity or allergy to Diosmin, Hesperidin, or any other component of the formulation. Furthermore, the medicine must not be used by individuals experiencing active bleeding or those classified as being at a high risk of hemorrhage.

Populations Requiring Restriction

Dioxel is not recommended for use in children and adolescents under 18 years of age due to a lack of established safety and efficacy data in this age group. Similarly, use is not recommended for pregnant women (as a precautionary measure) and is deemed inadvisable for breastfeeding women due to the absence of data regarding its excretion into human milk.

Conditional use requires caution in patients with pre-existing bleeding disorders, and discontinuation is mandatory before scheduled surgery. Official regulatory labeling does not define specific contraindications or dose limitations based solely on renal or hepatic impairment.

Dioxel: Interactions with Other Medicines and Products

The interaction profile for Dioxel (Diosmin and Hesperidin) is defined by the official reporting that no known drug interactions have been established by regulatory authorities. This information is derived directly from the official prescribing information, which supersedes generalized pharmacological predictions.

Official Regulatory Interaction Status

Interaction Type	Regulatory Status (Official Documentation)
Documented Drug-Drug Interactions	None established; regulatory labels state “no known drug interactions.”
Formal Contraindicated Combinations	None listed; no specific medicinal products are prohibited for co-administration.
Interactions with Food, Alcohol, or Supplements	None documented; the official label specifies “Food and drink: Not applicable.”

Understanding the Official Profile

The formal regulatory documentation indicates that no cases of drug interaction have been reported since the product was first marketed. Consequently, the official labeling does not require specific restrictions on co-administering Dioxel with other medicines.

This absence of documented interactions means the regulatory structure does not impose mandatory dose timing separation rules, nor does it list any specific medicines that alter Dioxel’s exposure through metabolic pathways, such as CYP enzymes or drug transporters. The profile confirms that there are no interaction-related restrictions tied to food, alcohol, or herbal products.

Dioxel operates as a phlebotropic agent, primarily targeting the microcirculatory and vascular endothelium. Following oral administration, the constituent diosmin is rapidly metabolized to its aglycone, diosmetin, which is then absorbed. The drug functions as a vascular protective agent via multiple mechanistic pathways.

At the cellular level, Dioxel acts by decreasing the expression of select endothelial adhesion molecules. This modulation restricts the activation, subsequent migration, and adherence of circulating leukocytes to the capillary endothelium, thereby reducing local inflammatory processes. This inhibition leads to a diminished downstream release of inflammatory mediators, including oxygen-free radicals, prostaglandins, and thromboxane, resulting in a systemic decrease in capillary hyperpermeability.

Physiologically, the drug enhances venous tone through a mechanism that involves increasing noradrenaline activity on the smooth muscle cells of vein walls. Furthermore, it supports lymphatic drainage by increasing the frequency and intensity of lymphatic contractions. This combined action modulates pressure dynamics within the vascular system.

Dioxel is a medicine administered solely via the oral route in the form of a film-coated tablet. The administration protocol is determined by the specific use case, requiring distinct dosage patterns for chronic support versus short-term acute episodes. All tablets must be consistently taken with meals.

Official Dosing and Frequency

Condition	Daily Dose (MPFF)	Frequency and Duration
Chronic Venous Insufficiency	1000 mg (2 tablets)	Taken in divided doses daily, such as at midday and evening. May be used for up to six months.
Acute Hemorrhoidal Attack	3000 mg (6 tablets) for 4 days, then 2000 mg (4 tablets) for 3 days.	The entire high-dose course is a fixed 7-day regimen.

Administration Requirements and Handling

For chronic use, the daily intake is typically structured as one tablet taken midday and one in the evening, ensuring the dose is split. The requirement to administer Dioxel with meals is a key procedural condition for proper use.

In the event a dose is missed, the patient should skip the missed dose entirely and resume the regular schedule; the dose must not be doubled to compensate. The medicine is not generally recommended for use in children or adolescents, as there is limited data in those age groups. The fixed seven-day duration for the acute regimen ensures the specific use context is adhered to, defining the procedural length of the intensive treatment phase.

Dioxel: Recent Clinical Evidence

Research on Action

Research has explored whether the drug may influence the inflammation associated with the condition. Studies have investigated the duration and magnitude of change in reported symptoms during acute episodes, providing context for the observed effects. The compound is described as a venoactive drug.

Key Efficacy Findings

The 2022 Core RCT

A large-scale randomized controlled trial (RCT) in 2022 reported a mean change in the primary outcome measure (symptom severity score) that was 15% different compared to placebo. Secondary data examined the impact on quality of life scores and the frequency of symptomatic flare-ups.

Combination Therapy Trials

A Phase 3 study evaluated the combination therapy, reporting a change in pain and fatigue levels in a number of participants. The study also collected data on specific endpoints associated with the condition.

Safety and Administration Protocol

Dosing and Compliance

The study protocol defined the administration schedule for participants, which included monitoring non-compliance and analyzing its effect on the measured endpoint. This information describes the context of the trial, not patient instructions.

Long-term Documentation

Long-term studies documented participant events and health status over time, with one study duration spanning at least one year. Research explored whether the drug influenced the progression of the disease in early-stage patients. Follow-up studies are ongoing to document extended participant observation.

Key Studies & References

1. Venoactive Drugs, Summary of the Clinical Trials and Guidelines - Annals of Phlebology (2021)
2. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF) - PubMed (Review of evidence)
3. Course duration for venoactive-drug treatment in chronic venous disease - Servier - Phlebolymphology (Focus on administration duration and efficacy)

Common questions about Dioxel (FAQ)

Q: What color are Dioxel film-coated tablets?

Official product information is the authoritative source for describing the physical characteristics of the tablets. While the form is designated as a film-coated tablet, the exact color is typically specified on the official label. You should consult the packaging or official label for the description of the tablets.

Q: Should Dioxel be taken at a specific time of day?

Official product information emphasizes taking Dioxel with meals. For chronic use, the regulatory documentation suggests dividing the daily dose into parts, such as one tablet at midday and one in the evening. The official documentation for the acute use regimen does not specify a precise time of day, only that the doses should be taken with food.

Q: Can I crush or chew the Dioxel tablet if I have trouble swallowing?

The official product information clarifies that Dioxel is manufactured as a film-coated tablet. The manufacturer's instructions on the official label are the only source that indicates whether the tablet is intended to be broken, chewed, or crushed. If the product label does not specifically permit breaking or altering the tablet, the product is generally intended to be swallowed intact, as the film coating and formulation are designed for proper use when swallowed whole.

How to Store and Dispose of Dioxel?

Storing Dioxel correctly helps ensure the stability of the active ingredients throughout the medicine's shelf-life. The official regulatory documents define clear, mandatory conditions for storage, safety, and disposal.

Requirement Area	Official Regulatory Statement
Storage Temperature	Store below 30 C (Thirty degrees Celsius).
Child Safety	Keep out of the sight and reach of children.
Handling	No special handling precautions are required for the tablets.
Disposal	No specific special requirements are mandated for the disposal of unused or expired product.

The medicine's stability is maintained under controlled ambient temperatures, as specified in the official labeling. The disposal of any unused or expired tablets should follow local pharmaceutical guidelines, typically involving returning the product to a collection point, as it is not classified as hazardous waste.